| Literature DB >> 26274504 |
Hong Zhao1, Lichen Xu1, Huihui Dong1, Jianhua Hu1, Hainv Gao1, Meifang Yang1, Xuan Zhang1, Xiaoming Chen1, Jun Fan1, Weihang Ma1.
Abstract
Vibrio vulnificus is a common gram-negative bacterium, which might cause morbidity and mortality in patients following consumption of seafood or exposure to seawater in Southeast China. We retrospectively analyzed clinical data of patients with laboratory confirmed V. vulnificus infection. Twenty one patients were divided into a survival group and a non-surviving (or death) group according to their clinical outcome. Clinical data and measurements were statistically analyzed. Four patients (19.05%) died and five patients gave positive cultures from bile fluid, and 16 other patients gave positive culture from blood or blisters. Ten patients (47.62%) had an underlying liver disease and marine-related events were found in sixteen patients (76.2%). Patients with heavy drinking habits might be at increased mortality (p = 0.028). Clinical manifestations of cellulitis (47.6%), septic shock (42.9%) and multiple organ failure (28.6%) were statistically significant when comparing survivors and non-survivors (p = 0.035, p = 0.021 and p = 0.003, respectively). The laboratory results, including hemoglobin < 9.0 g/L (p = 0.012), platelets < 2.0 × 109 /L, prothrombin time activity (PTA) <20%, decreased serum creatinine and increased urea nitrogen were statistically significant (p = 0.012, p = 0.003, p = 0.028 and p = 0.028, respectively). Patients may be at a higher risk of mortality under situations where they have a history of habitual heavy alcoholic drink consumption (p = 0.028, OR = 22.5, 95%CI 1.5-335.3), accompanied with cellulitis, shock, multiple organ failure, and laboratory examinations that are complicated by decreased platelets, hemoglobin and significantly prolonged prothrombin time (PT).Entities:
Mesh:
Year: 2015 PMID: 26274504 PMCID: PMC4537211 DOI: 10.1371/journal.pone.0136019
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Fig 1Seasonal distribution of V. vulnificus infections at the First Affiliated Hospital of Zhejiang University, School of Medicine, Hangzhou, China.
Demographic and clinical presentations.
| Characteristic | Survivors (n = 17) | Deaths (n = 4) | OR(95%CI) | p-value |
|---|---|---|---|---|
| Age (years) | ||||
| Mean ± SD | 54.82 ± 8.74 | 53.50 ± 9.00 | 0.789 | |
| Range | 39–68 | 42–64 | ||
| Gender | ||||
| Male/female | 10/7 | 4/0 | 0.7(0.5–1.0) | 0.255 |
| Blood type | ||||
| A/B/O/AB | 4/4/6/3 | 2/2/0/0 | 0.091 | |
| Comorbidities | ||||
| None | 4 | 1 | 0.9(0.1–11.5) | 1.000 |
| Heavy drinking | 2 | 3 | 22.5(1.5–335.3) | 0.028 |
| Liver disease | 9 | 1 | 0.3(0.0–3.5) | 0.586 |
| Clinical symptoms | ||||
| Fever | 17 | 4 | ||
| Pain | 12 | 4 | 1.3(1.0–1.8) | 0.532 |
| Swelling | 9 | 4 | 1.4(1.0–2.1) | 0.131 |
| Hemorrhagic bulla | 9 | 2 | 0.9(0.1–7.9) | 1.000 |
| Cellulitis | 6 | 4 | 1.7(1.0–2.8) | 0.035 |
| Gastrointestinal discomforts | 7 | 0 | 0.7(0.5–1.0) | 0.255 |
| Septic shock | 5 | 4 | 1.8(1.0–3.2) | 0.021 |
| Multiple organ failure | 2 | 4 | 3.0 (1.0–9.3) | 0.003 |
| Pathogens cultured site | ||||
| Bile/not bile culture | 5/12 | 3/1 | 1.3(1.0–5.8) | 0.532 |
Note
&: Chronic liver diseases include hepatitis B, and C, alcoholic hepatitis, liver cirrhosis, liver transplantation, and liver hepatic carcinoma.
*: Gastrointestinal discomfort including abdominal pain, vomiting, and diarrhea.
Fig 2Clinical syndromes of V. vulnificus infections in the First Affiliated Hospital of Zhejiang University, School of Medicine, Hangzhou, China.
Fig 3V. vulnificus infection that presented as swelling, Hemorrhagic bulla and phlegmon are observed on the right hand.
Laboratory results measured between survivors group and deaths group.
| Laboratory results | Survivors(n = 17) | Deaths (n = 4) | p-value |
|---|---|---|---|
| WBC (mean ± SD, ×109/L) | 6.87 ± 4.59 | 11.53 ± 9.65 | 0.158 |
| > 10×109/L | 4 | 1 | 1.000 |
| < 4×109/L | 5 | 1 | 1.000 |
| Hemoglobin (mean ± SD, g/L) | 111.94 ± 16.57 | 87.00 ± 8.98 | 0.010 |
| < 90 g/L | 1 | 3 | 0.012 |
| Platelets | 85.24 ± 61.65 | 8.75 ± 1.50 | 0.000 |
| < 2.0×109/L | 1 | 3 | 0.012 |
| PT (mean ± SD, s) | 17.38 ± 4.85 | 42.30 ± 5.31 | 0.004 |
| PTA<20% | 0 | 3 | 0.003 |
| Total bilirubin (mean ± SD, mmol/L) | 95.58 ± 84.51 | 198.67 ± 169.67 | 0.165 |
| >increased / normal | 6/11 | 2/2 | 0.618 |
| ALT (mean ± SD, U/L) | 90.00 ± 94.35 | 169 ± 175.81 | 0.313 |
| >2 times ULN/normal | 6/11 | 1/3 | 1.000 |
| AST (mean ± SD, U/L) | 125.30±91.06 | 814.00 ± 1045.36 | 0.372 |
| >2 times ULN/ normal | 6/11 | 3/1 | 0.272 |
| Serum creatinine (mean ± SD, μmol/L) | 83.30 ± 50.95 | 375.00 ± 257.46 | 0.187 |
| < normal / normal | 2/15 | 3/1 | 0.028 |
| Urea nitrogen (mean ± SD, mmol/L) | 7.044 ± 4.07 | 34.96 ± 16.97 | 0.182 |
| ≥normal / normal | 2/15 | 3/1 | 0.028 |
Note: ULN, the upper limit of normal. At our hospital, the normal range for ALT was 5–40 U/L, the normal range for AST was 5–37 U/L, the normal range for serum creatinine was 40–108 μmol/L, and the normal range for urea nitrogen was 1.7–8.3 mmol/L.
Treatment strategies and clinical outcomes.
| Treatment strategies | Survivors(n = 17) | Deaths (n = 4) | p-value |
|---|---|---|---|
| Antibiotic treatments | 0.272 | ||
| Only on antibiotic | 6 | 3 | |
| Piperacillin-tazobactam | 2 | 0 | |
| Cefoperazone-sulbactam | 1 | 2 | |
| Imipenem-cilastatin | 2 | 0 | |
| Meropenem | 0 | 1 | |
| Quinolone | 1 | 0 | |
| More than one antibiotic | 7 | 1 | |
| Surgical interventions | |||
| Yes/No | 5/12 | 0/4 | 0.532 |
| The time between the injuries or the onset of symptoms to hospital (mean ± SD, day) | 2.29±2.34 | 2.25±0.96 | 0.971 |
| <one />one | 10/7 | 3/1 | 1.000 |
| Range | 1–10 | 1–3 | |
| Hospitalization (mean ± SD, day) | 39.71±32.49 | 15.00±8.72 | 0.155 |
| Range | 7–109 | 2–20 |